FDA approves Advair Diskus 100/50 mcg for children four to eleven
RESEARCH TRIANGLE PARK, N.C., April 22, 2004 -- GlaxoSmithKline announced that the FDA has approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.
Advair contains an inhaled corticosteroid (ICS) and a
long-acting beta2-agonist (LABA) and is the only long-term
preventative product that treats the two main components of asthma
-- airway inflammation and bronchoconstriction. According to the
National Institutes of Health's treatment guidelines, an ICS in
conjunction with a LABA is a preferred treatment for patients who
still have symptoms while taking low dose ICS.
"Advair is a highly effective treatment for asthma, and it is great news that it is now available for children as young as four," said Joseph Spahn, M.D., Associate Professor of Pediatrics at National Jewish Medical Center and University of Colorado Health Sciences Center. "Not only will it help prevent asthma symptoms, but its twice daily dosing is convenient for both parents and children.
"Treating inflammation and airway constriction is critical to controlling asthma symptoms," said Dr. Spahn. "An important advantage of Advair is that it combines two highly effective medicines in one device to treat these components."
Advair has been available in the US since April 2001 to treat asthma in patients 12 years of age and older and is the most commonly prescribed inhaled asthma maintenance therapy in the United States.
The safety profile of Advair was studied in a 12-week trial conducted with 203 children, four to 11 years old with asthma, who were symptomatic on low doses of an inhaled corticosteroid. The primary objective of this study was to evaluate the safety of Advair 100/50 twice daily compared with fluticasone propionate (FP) 100mcg twice daily. The results showed that Advair had a similar safety profile to FP. The study also included secondary efficacy measures of lung function as measured by FEV1 (forced expiratory volume in one second) in children six to 11. Patients receiving Advair and patients receiving FP experienced improved FEV1 over the course of the study.
Advair is a long-term maintenance treatment for asthma in patients four and older. Advair won't replace fast-acting inhalers for sudden symptoms and should not be taken more than twice a day. Rare but serious asthma episodes and asthma-related fatalities occurred in a study with Serevent, one of the components of Advair. These risks may be greater in African Americans. While adjusting to a switch from an oral steroid, like prednisone, to the inhaled steroid in Advair, patients and doctors should be very careful, as patients may be less able to heal after surgery, infection, or serious injury. Patients should tell their doctor if they have a heart condition or high blood pressure. Some people may experience increased blood pressure, heart rate, or changes in heart rhythm. Advair contains an inhaled corticosteroid. Inhaled corticosteroids, as well as poorly controlled asthma, may cause a reduction in growth rate. The long term effect on final adult height is unknown. Patients should see their doctor if their asthma does not improve.
Posted: April 2004